Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases
Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.
Prana today provided a business update on its development portfolio of potential neurodegenerative treatments.
Prana AGM webcast
Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"